bpc 157 i tb 500 BPC-157 / TB-500 Blend (Dual Peptide) BPC-157 + TB-500 Research Compound
Description
AOD 9604 in Obesity and Metabolic Research Short-Term Weight-Loss Trials AOD 9604 was advanced into human trials as an oral anti-obesity candidate
Respectez les conditions de stockage indiques sur la bote de 6 ampoules
Preclinical studies show it enhances insulin sensitivity, promotes fat oxidation, improves exercise capacity, and counters age-related metabolic decline [1] [4]
The SURMOUNT-1 trial showed meaningful weight loss at every dose level, with 5mg producing an average 15% body weight reduction over 72 weeks
